NEW YORK, Nov. 19 /PRNewswire-Asia-FirstCall/ -- Zacks Equity Research has
initiated investment research coverage on Sinobiopharma, Inc. with an Outperform and six month target price of $0.80. Jiangsu, China-based SNBP, known domestically as Dong Ying ...
[Stockwatch - 11/19/2009]